A553all groups, costs increased gradually leading up to surgery and peaked in the month after surgery. Three years pre-surgery, mean monthly total cost was in the successful group: € 531; undetermined: € 882; persistent pain: € 891; and to-be SCS patients: € 1,153. Three years post-surgery, the corresponding cost was € 509, € 1,105, € 1,269 and € 3,346, respectively. The groups with persistent pain, undetermined outcome and to-be SCS patients had worse baseline QoL (0.26, 0.33, 0.20, respectively) and worse QoL post-surgery (0.46, 0.62, 0.24), compared with the successful group (baseline: 0.34, post-surgery 0.82). ConClusions: There was an apparent association between outcome, costs and post-surgery QoL. Patients with undetermined outcome, persistent pain and to-be-SCS patients had less QoL improvement post-surgery and higher costs both before and after surgery compared with the successful group.
Background
Limited real-world data are available in Europe, especially France, regarding the therapeutic management of anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD).
Methods
This retrospective, longitudinal, observational study was based on medical records from the MEDIAL database of not-for-profit dialysis units in France. From January to December 2016, we included eligible patients (≥18 years), with a diagnosis of CKD and receiving maintenance dialysis. Patients with anaemia were followed up for 2 years after inclusion. Patient demographic data, anaemia status, CKD-related anaemia treatments, and treatment outcomes including laboratory test results were evaluated.
Results
Of 1632 DD CKD patients identified from the MEDIAL database, 1286 had anaemia; 98.2% of patients with anaemia were receiving haemodialysis at index date (ID). Of patients with anaemia, 29.9% had haemoglobin (Hb) levels of 10–11 g/dL and 36.2% had levels of 11–12 g/dL at ID. Furthermore, 21.3% had functional iron deficiency and 11.7% had absolute iron deficiency. The most commonly prescribed treatments at ID for patients with DD CKD-related anaemia were intravenous (IV) iron with erythropoietin-stimulating agents (ESAs) (65.1%). Among patients initiating ESA treatment at ID or during follow-up, 347 (95.3%) reached the Hb target of 10–13 g/dL and maintained response within the target Hb range for a median duration of 113 days.
Conclusions
Despite combined use of ESAs and IV iron, duration within the Hb target range was short, suggesting that anaemia management can be further improved.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.